Reviva Pharmaceuticals Holdings, Inc. (RVPH)
- Zacks Small Cap Research
RVPH: Brilaroxazine Enthusiasm Abounds
By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT March Update Since our previous report that was submitted on the occasion of Reviva Pharmaceutical Holdings, Inc’s (NASDAQ:RVPH) third quarter results, the company has reported the award of new patents, completed brilaroxazine drug-drug interaction studies and an updated stakeholders on the Phase III RECOVER trial. CEO
- GlobeNewswire
Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference
CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 35th Annual Roth Conference, taking place March 12-14 in
- Simply Wall St.
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Reviva...
